checkAd

C4XD Agreement with AstraZeneca

C4XD signs exclusive global licence worth up to $402 million1 with AstraZeneca for the development and commercialisation of NRF2 Activator programmeC4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and …

C4XD signs exclusive global licence worth up to $402 million1 with AstraZeneca for the development and commercialisation of NRF2 Activator programme

C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties

Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company

MANCHESTER, ENGLAND / ACCESSWIRE / November 28, 2022 / C4X Discovery Holdings plc (AIM:C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million1, for its NRF2 Activator programme. AstraZeneca will develop and commercialise an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).

Under the terms of the agreement, C4XD will receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront. In addition, C4XD is eligible to receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialisation.

Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca said: "At AstraZeneca, we are committed to transforming care in respiratory and immune-mediated disease and move beyond symptom control. Our alliance with C4XD adds an important new asset to our portfolio to push the boundaries of science by targeting underlying disease drivers to potentially modify the course of these diseases."

Dr Clive Dix, CEO of C4XD, added: "Drug Discovery is inherently scientifically complex, and it is through our unique expertise and proprietary cutting-edge technologies that C4XD is yet again proving itself as an exemplar in this field. NRF2 is thought to be a critical but challenging anti-inflammatory target, and I am proud of the work by our team to achieve a broad stable of intellectual property for this programme, leading to our third significant deal with a truly world-renowned industry leader. The COPD market alone is worth close to $20 billion and rising.2 But, more importantly, I know that in AstraZeneca's hands, with their scientific, technical and commercial expertise, our NRF2 Activator programme has the potential to deliver life changing treatments for the millions of patients suffering with COPD across the world."

Seite 1 von 3


Wertpapier



0 Kommentare
Nachrichtenquelle: Accesswire
 |  227   |   |   

Schreibe Deinen Kommentar

Disclaimer

C4XD Agreement with AstraZeneca C4XD signs exclusive global licence worth up to $402 million1 with AstraZeneca for the development and commercialisation of NRF2 Activator programmeC4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and …

Nachrichten des Autors

804 Leser
364 Leser
276 Leser
244 Leser
232 Leser
216 Leser
216 Leser
212 Leser
196 Leser
196 Leser
1072 Leser
832 Leser
804 Leser
748 Leser
716 Leser
708 Leser
704 Leser
696 Leser
664 Leser
624 Leser
4532 Leser
2855 Leser
1735 Leser
1529 Leser
1284 Leser
1255 Leser
1240 Leser
1125 Leser
1072 Leser
942 Leser